CardioQ saves over $4K per patient
UK-based hemodynamic montoring firm, the Deltex Medical Group, has reported encouraging preliminary findings from an audit of the use of the its CardioQ monitor in liver surgery.
Doctors and managers at a European teaching hospital evaluated CardioQ in 10 patients undergoing major liver surgery and compared the use of disposable equipment, whole blood and blood products for these patients with historical averages and found that, on average, use of blood products was significantly less for the monitored group.
According to the firm, cost savings, taking into account the purchase of the Deltex Medical probe and the reduction in whole blood, blood products and ancillary equipment used, but excluding savings from shorter length of stay, were approximately 3,500 euros per patient ($4,224).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze